

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O^6 -benzylguanine

Tomio Ueno,^{1,2} Sae Hee Ko,¹ Elizabeth Grubbs,¹ Yasunori Yoshimoto,^{1,2} Christi Augustine,¹ Zeinab Abdel-Wahab,¹ Tsung-Yen Cheng,¹ Omar I. Abdel-Wahab,¹ Scott K. Pruitt,¹ Henry S. Friedman,¹ and Douglas S. Tyler¹

¹Department of Surgery, Duke University Medical Center, Durham, North Carolina and ²Department of Surgery II, Yamaguchi University School of Medicine, Yamaguchi, Japan

Abstract

This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O^6 -benzylguanine (O^6 BG), an inhibitor of the DNA repair enzyme O^6 -alkylguanine-DNA alkyltransferase (AGT). Using a nude rat s.c. human melanoma xenograft model of the extremity, tumors were analyzed for AGT level 2 to 3 hours after the i.p. injection of 3.5 to 70.0 mg/kg O^6 BG to inhibit AGT activity. Survival studies were conducted using animals that were treated with a 15-minute isolated limb infusion with 10% DMSO in PBS (control), temozolomide alone, or temozolomide in conjunction with single or multiple doses of i.p. O^6 BG. Tumor volume and toxicity level were monitored every other day. Administration of 3.5 mg/kg O^6 BG depleted tumor AGT activity by 93.5% ($P < 0.01$). Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O^6 BG, or vehicle combined with O^6 BG showed no significant tumor responses compared with controls. Whereas use of regional temozolomide alone at a higher dose (750 mg/kg) showed some degree of tumor response, regional temozolomide

given in conjunction with multiple dosages of O^6 BG showed a marked ($P < 0.01$) reduction in tumor growth with minimal toxicity. Our findings suggest that AGT modulation by the administration of O^6 BG in combination with temozolomide regional chemotherapy leads to a significant improvement in melanoma antitumor responses. Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials. [Mol Cancer Ther 2006; 5(3):732–8]

Introduction

Regional failure in patients with extremity melanoma is a significant problem. Aggressive therapy in the form of amputation suggests that 25% to 35% of these patients may have disease confined to the extremity (1). Isolated limb infusion or perfusion with cytotoxic agents is frequently used for this clinical problem. Melphalan (L-phenylalanine mustard) has been accepted as the most widely used drug in the regional setting for advanced extremity melanoma although many cytotoxic drugs have been studied. Recently, however, we have shown in a clinically relevant animal model of regionally advanced melanoma that regional temozolomide has better anti-tumor activity than either systemic temozolomide or regional melphalan (2).

Attempts at modulation of mechanisms that interfere with the optimal effectiveness of chemotherapeutic agents have been explored previously *in vitro*, but *in vivo* experiments have been limited due to increased systemic toxicity when chemotherapy and modulators are used together (3). Utilization of these strategies in a regional setting has the advantage of minimizing the systemic side effects of combination therapy while maximizing the effect regionally on the tumor. We have previously investigated modulation of putative resistance mechanisms in the context of regional therapy for melanoma and showed marked improvements in the therapeutic index of melphalan by interfering with the glutathione detoxification system (3–5). The specific aim for this project was to define if the therapeutic index of regional melanoma therapy with temozolomide can be enhanced using systemic inhibition of O^6 -alkylguanine-DNA alkyltransferase (AGT), the predominant mechanism of resistance to this methylating agent (6), by administration of the drug O^6 -benzylguanine (O^6 BG) in an animal model that parallels the clinical situation of in-transit disease in humans.

Received 4/4/05; revised 12/4/05; accepted 1/11/06.

Grant support: Veterans Affairs Merit Review (D.S. Tyler), Veterans Affairs Institute of Medical Research (D.S. Tyler), and Correlative Science Committee of the American College of Surgeons Oncology Group (D.S. Tyler).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Douglas S. Tyler, Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710. Phone: 919-684-6858; Fax: 919-684-6044. E-mail: tyler002@acpub.duke.edu

Copyright © 2006 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-05-0098

Materials and Methods

Animals and Tumor Inoculation

Female athymic nude rats (age, 5–7 weeks; RHU-M, Harlan, Indianapolis, IN) were housed in a temperature-controlled room with a 12-hour light-dark cycle. A standard laboratory diet and water were provided *ad libitum*.

Within 3 days after irradiation at a dose of 500 cGy to facilitate growth of human melanoma xenografts, the rats were injected s.c. in the right distal hind limb just proximal to the ankle with 5×10^6 culture human melanoma cells (DM6; ref. 3). Xenografts were measured every other day with vernier calipers in two perpendicular dimensions and tumor volume was calculated according to the following formula: [(length) \times (width)²] / 2 (5). All aspects of the experimental protocol were approved by the Durham Veterans Affairs Medical Center Institutional Animal Care and Use Committee.

⁶O⁶BG Dosing Study

We routinely prepared fresh ⁶O⁶BG stock solution of 2 mg/mL in 40% polyethylene glycol-400 (PEG) in PBS. The ⁶O⁶BG solution of interest was then made by further dilution of ⁶O⁶BG stock solution with 40% PEG in PBS according to the given dosing regimen. A solution of 40% PEG in PBS was used as the vehicle control for the ⁶O⁶BG experiments.

To evaluate the inhibitory effect of ⁶O⁶-benzylguanine (⁶O⁶BG; Sigma Chemical Co, St. Louis, MO) on AGT activity in the regional nude rat human melanoma xenograft model, we compared tumor and muscle AGT levels from four groups of rats with a similar size xenograft by giving 3.5, 17.5, 35, or 70 mg/kg ⁶O⁶BG i.p. ($n = 3$ in each group). Two to three hours after the administration of ⁶O⁶BG, both tumor and muscle tissues were harvested, immediately snap frozen, and analyzed for AGT. Samples were removed under general anesthesia to prevent the loss of enzyme activity. To measure the baseline AGT activity of tumor and muscle, tissues were harvested from four rats 2 to 3 hours after i.p. administration vehicle (40% PEG in PBS).

AGT Determination

Samples of harvested tumor xenografts were weighed and extracts were prepared by adding 2 mL of 50 mmol/L Tris (pH 7.5), 0.1 mmol/L EDTA, and 5 mmol/L DTT buffer per gram of tissue weight. Samples were homogenized for 1 minute, sonicated for 1 minute, and centrifuged at $14,000 \times g$ for 30 minutes. The assay for AGT activity was done as previously described by Domoradski et al. (7). Briefly, AGT activity was measured as the removal of ⁶O⁶-[³H]-methylguanine from a [³H]-methylated DNA substrate (5.8 Ci/mmol) following incubation with tissue extract at 37°C for 30 minutes. The DNA was precipitated by adding ice-cold perchloric acid (0.25 N) and hydrolyzed by the addition of 0.1 N HCl at 70°C for 30 minutes. Following filtration using a microfilter apparatus, the modified bases are separated by reverse-phase high-performance liquid chromatography with 0.5 mol/L ammonium formate (pH 4.5) containing 5.5% methanol.

Protein is determined by the method of Bradford and the amount of ⁶O⁶-methylguanine released from the DNA substrate per mg of protein was calculated. All AGT levels are expressed as mean \pm SE.

Isolated Limb Infusion Technique

Isolated limb infusion was done as previously described (2). Briefly, under general anesthesia, the right femoral artery and vein were isolated. The proximal femoral artery and vein were then ligated. The femoral artery was cannulated and the arterial catheter was attached to a peristaltic pump. The femoral vein was then cannulated. Once both cannulas were in place, the pump and tubing were primed with saline, the thigh tourniquet was tightened, and saline was initiated at a flow rate of 1.5 mL/min. After ensuring an appropriate flow, the limb was infused with the solution of interest. A 15-minute infusion was done at a flow rate of 1.5 mL/min, followed by a 1-minute wash-out infusion with saline at a flow rate of 3.0 mL/min. Following the wash, the arterial and venous cannulas were removed and the femoral artery and vein were ligated.

Temozolomide Treatment in the Absence and Presence of ⁶O⁶BG

We have previously reported a dose-escalation study using regional temozolomide (350, 750, 1,000, 1,500, and 3,000 mg/kg) in the same animal model used in this study (2). In the present study, temozolomide was administered as a single dosage via isolated limb infusion at the doses of 350 or 750 mg/kg infused limb weight. Ten percent of the rat body weight was assumed as the limb weight.

We prepared fresh temozolomide stock solution of 4 mg/mL in 10% DMSO in PBS. Standard formulations of temozolomide were kindly provided by Dr. W. Robert Bishop (Schering-Plough Research Institute, Kenilworth, NJ). Infusate was made by further dilution of temozolomide stock solution into 22.5 mL of 10% DMSO in PBS according to the given dosing regimen for a 15-minute infusion.

Modulation on AGT activity was done with i.p. ⁶O⁶BG following the results of ⁶O⁶BG dosing study. Doses of ⁶O⁶BG were prepared in the same manner as described above.

Once tumors reached 12 mm in greatest dimension, rats were randomly assigned to one of the following subgroups:

- (1) Isolated limb infusion without modulation of AGT
 - Isolated limb infusion with 10% DMSO
 - Isolated limb infusion with 350 mg/kg temozolomide
 - Isolated limb infusion with 750 mg/kg temozolomide
- (2) Isolated limb infusion in combination with ⁶O⁶BG
 - Isolated limb infusion with 350 mg/kg temozolomide
 - Isolated limb infusion with 750 mg/kg temozolomide
- (3) Isolated limb infusion in combination with ⁶O⁶BG every 24 hours for 5 consecutive days (A total amount of ⁶O⁶BG per rat was 17.5 mg/kg.)
 - Isolated limb infusion with 10% DMSO
 - Isolated limb infusion with 350 mg/kg temozolomide
 - Isolated limb infusion with 750 mg/kg temozolomide

- (4) Systemic temozolomide in combination with O^6BG every 24 hours for 5 consecutive days
Isolated limb infusion following O^6BG administration was introduced two hours after the dosing.

Tumor Measurement and End Point

Tumors and any ulcer or full-thickness eschar were measured as described above. Tumor volume was calculated according to the same formula mentioned above and the volume of any ulcer or eschar was subtracted from the total tumor volume. Animals were euthanized either when a 500% change in tumor volume occurred or after 60 days.

Evaluation of Tumor Response and Toxicity

Time (in days) taken to reach a quintupling of tumor volume was calculated from tumor volume measurements using linear regression. The average tumor quintupling was then calculated and compared. Response to treatment was also assessed by growth delays and number of regressions. Growth delay (in days) was defined as the difference in tumor quintupling time in treated versus control animals. Tumor regression was defined as a tumor of which the volume decreased over two consecutive measurements (8).

Rats were also monitored for general well-being, weight, and functional ability of leg following surgery to access the toxicity. Intra-animal weight gain or loss was calculated as a percentage of its baseline weight before surgery (day 0), and the mean nadir weight loss was calculated for each group. Toxicity was defined by assigning each rat a toxicity score as follows: grade 1, no subjective or objective evidence of reaction (normal walking pattern); grade 2, slight erythema and/or edema; grade 3, considerable erythema and/or edema (rodent does not use its hind limb in a useful manner but stands on it when rising); grade 4, obvious damage to the deep tissues (rat drags its hind limb without any function); grade 5, reaction that leads to autoamputation; and grade 6, animal death.

Statistical Analysis

The therapeutic indexes of the various treatments were assessed by ANOVA. When significant differences were detected in ANOVA, differences between means were checked by Bonferroni's method. Fischer's exact test was done for tumor regressions. $P < 0.05$ was considered significant.

Results

O^6BG Dosing Study

The activity of AGT before and after exposure to O^6BG is shown in Fig. 1. The control values show AGT levels after treatment with 40% PEG in PBS, which was the vehicle used to solubilize O^6BG . These values are no different than AGT values seen in the tumors of untreated animals (data not shown). Complete depletion of AGT activity in both tumors ($P < 0.01$) and muscle tissues ($P < 0.05$) within 2 to 3 hours was achieved by the administration of 17.5 and 35 mg/kg O^6BG . Use of a low dose of O^6BG (3.5 mg/kg) was




Figure 1. AGT inhibition by O^6BG in tumors and muscle tissues. Tumor and muscle AGT levels were measured in four groups of rats by giving 3.5, 17.5, 35, or 70 mg/kg O^6BG i.p. ($n = 3$ in each group). Two to three hours after the administration, samples were harvested and used for AGT determination. The administration of 17.5 and 35 mg/kg O^6BG showed complete depletion of AGT activity in both tumors and muscle tissues. A low dose of O^6BG (3.5 mg/kg) also suppressed the activity of AGT in tumors by 93.5%; however, it did not significantly inhibit the activity of AGT in muscle tissues. Bars, SE.

also effective and suppressed the activity of AGT in tumors by 93.5% ($P < 0.01$). All rats that received 70 mg/kg O^6BG and one of the three rats treated with 35 mg/kg O^6BG died before tissue harvest. In view of the toxicity at higher dosing, the lowest dose tested that showed efficacy (3.5 mg/kg) was used in the remaining survival studies with only the frequency of dosing being changed.

Improvement of Therapeutic Index with Temozolomide in Conjunction with O^6BG

Regional Temozolomide without O^6BG . Regional temozolomide at a concentration of 350 mg/kg without modulation of AGT was ineffective at delaying tumor growth although a small increase in the number of regressions compared with the group treated with regional 10% DMSO in PBS (Table 1) was seen. Using a dose of 750 mg/kg regional temozolomide alone, a slight increase in quintupling time was observed, which was not significantly different from the 10% DMSO control.

Regional Temozolomide with Single Dose of O^6BG . Using a dose of 350 mg/kg regional temozolomide in conjunction with a single dose of 3.5 mg/kg O^6BG showed increases in tumor growth delay and quintupling time that did not reach statistical significance. No increase in the number of regressions was seen over temozolomide alone (Fig. 2A; Table 1). However, 750 mg/kg of regionally administered temozolomide with a single dose of O^6BG systemically led to a significant prolongation of tumor growth delay ($P < 0.01$; Fig. 2B) and increased number of tumor regressions ($P < 0.05$; Table 1).

Regional Temozolomide with Multi-Dose of O^6BG . When O^6BG was administered systemically for 5 consecutive days, rats treated using regional isolated limb infusion with 350 or 750 mg/kg temozolomide showed significant prolongation of tumor growth delay ($P < 0.01$; Fig. 2A and B) and increased number of tumor regressions ($P < 0.01$; Table 1) compared with the group treated using isolated limb infusion with 10% DMSO in conjunction with the multi-dose course of O^6BG for 5 days. In contrast, animals who received systemic temozolomide combined with multiple dosages of O^6BG systemically showed no

Table 1. Effects of temozolomide and O^6 BG on DM6 melanoma xenografts

Group	Quintupling time, mean \pm SE (d)	Growth delay (d)	No. regressions
No modulation			
ILI + 10% DMSO (control; $n = 6$)	18.8 \pm 2.2	—	1/6
ILI + 350 mg/kg temozolomide ($n = 6$)	17.3 \pm 2.4	-1.5	3/6
ILI + 750 mg/kg temozolomide ($n = 6$)	23.8 \pm 4.3	5.1	3/6
ILI + 750 mg/kg temozolomide ($n = 6$) with 40% PEG in PBS systemically \times 5 d	20.6 \pm 3.1	3.3	2/6
Modulation with 3.5 mg/kg O^6 BG \times 1 d			
ILI + 350 mg/kg temozolomide ($n = 6$)	30.4 \pm 4.8	11.7	3/6
ILI + 750 mg/kg temozolomide ($n = 6$)	42.5 \pm 8.2*	23.8	5/6 [†]
Modulation with 3.5 mg/kg O^6 BG \times 5 d [‡]			
ILI + 10% DMSO (control; $n = 6$)	17.3 \pm 2.5	—	0/6
ILI + 350 mg/kg temozolomide ($n = 6$)	39.8 \pm 4.5 [§]	22.6	5/6 [§]
ILI + 750 mg/kg temozolomide ($n = 6$)	50.2 \pm 5.5 [§]	32.9	6/6 [§]
Systemic 35 mg/kg temozolomide ($n = 6$)	13.7 \pm 3.2	-3.5	0/6

Abbreviation: ILI, isolated limb infusion.

* $P < 0.01$, versus ILI + 10% DMSO.

[†] $P < 0.05$, versus ILI + 10% DMSO.

[‡]ILI with temozolomide or 10% DMSO was done 2 hours after first O^6 BG i.p. administration. O^6 BG was given every 24 hours for the next 4 days.

[§] $P < 0.01$, versus ILI + 10% DMSO with 3.5 mg/kg O^6 BG for consecutive 5 days.

significant tumor growth delay (Table 1). Finally, to confirm that the observed activity of O^6 BG was not related to the vehicle (40% PEG in PBS) in which it was mixed, a series of experiments was also carried out using vehicle alone as a systemic modulator. As shown in Fig. 2B and Table 1, there is no difference in the antitumor activity of temozolomide when given in the presence or absence of 40% PEG in PBS.

Evaluation of Toxicity. As shown in Table 2, no significant difference was found among groups in mean nadir weight loss or in maximum weight gain who underwent regional therapy using intra-arterial temozolomide in conjunction with systemic O^6 BG. There were no rats who died or developed an autoamputation secondary to drug toxicity using combination therapy. The group which received systemic temozolomide in conjunction with multi-dose of O^6 BG for 5 days showed the most severe mean nadir weight loss.

Discussion

In a quest for new regional chemotherapeutic agents against advanced extremity melanoma, we started to explore temozolomide (temozolomide), which is a novel methylating agent and is one of the more effective single-agent therapies for metastatic melanoma (9, 10). However, because its i.v. formulation is not currently available, temozolomide has not been tried as a regional chemotherapy in humans. We initially examined dose-escalation studies using regional and systemic temozolomide in a clinically relevant animal model of regionally advanced melanoma. We found that regional temozolomide had an antitumor effect as its dose was increased whereas systemic temozolomide had little antitumor effect even at a dose

exceeding the LD₁₀ in this model (2). Furthermore, when we compared the highest equitoxic dosages of regional melphalan, a gold standard drug in regional therapy, without heat, to regional temozolomide without heat, we found that temozolomide was significantly more effective in causing regressions and delaying tumor growth than melphalan (2). These findings suggest that temozolomide might be a promising new regional therapeutic agent.

The antitumor activity of temozolomide is a direct consequence of DNA methylation. The cytotoxic lesion is felt to be due to methylation of the O^6 position of guanine.




Figure 2. Effect of regional or systemic temozolomide with or without O^6 BG. The average tumor growth inhibition with systemic 35 mg/kg temozolomide with 3.5 mg/kg O^6 BG for 5 consecutive days and intra-arterial administration of 350 mg/kg temozolomide with or without O^6 BG (A) and intra-arterial 10% DMSO (control) or 750 mg/kg of intra-arterial administration of temozolomide with or without O^6 BG (B). Y axis, percent increase in tumor volume; X axis, days after treatment. Bars, SE.

Table 2. Adverse effects of temozolomide and O⁶BG on body weight

Group	Mean nadir weight loss, mean \pm SE (%)	Maximum weight gain, mean \pm SE (%)
No modulation		
ILI + 10% DMSO (control; <i>n</i> = 6)	-6.2 \pm 3.2	2.7 \pm 2.0
ILI + 350 mg/kg temozolomide (<i>n</i> = 6)	-5.4 \pm 1.0	1.2 \pm 1.9
ILI + 750 mg/kg temozolomide (<i>n</i> = 6)	-3.3 \pm 1.3	3.1 \pm 1.3
Modulation with 3.5 mg/kg O ⁶ BG		
ILI + 350 mg/kg temozolomide (<i>n</i> = 6)	-1.8 \pm 0.8	3.5 \pm 1.2
ILI + 750 mg/kg temozolomide (<i>n</i> = 6)	-5.3 \pm 1.9	3.9 \pm 1.5
Modulation with 3.5 mg/kg O ⁶ BG \times 5 d		
ILI + 10% DMSO (control; <i>n</i> = 6)	-3.3 \pm 1.4	3.0 \pm 1.5
ILI + 350 mg/kg temozolomide (<i>n</i> = 6)	-6.7 \pm 2.9	7.3 \pm 3.5
ILI + 750 mg/kg temozolomide (<i>n</i> = 6)	-7.5 \pm 1.6	4.4 \pm 1.6
Systemic 35 mg/kg temozolomide (<i>n</i> = 6)	-8.8 \pm 2.9	1.6 \pm 1.8

Unrepaired O⁶-methylguanine (O⁶MG) seems as an "adenine" base to the cell and it is paired with a thymine base (11). The function of a repair protein, AGT, in normal cells (as well as in tumor cells) involves removing chloroethylation or methylation damage from the O⁶-position of guanine. If AGT is present during the repair, O⁶MG bases are removed and DNA repair results in the correction of the mispairing that occurred due to the methylating agent (12). However, if AGT is not present, O⁶MG:T mispaired bases trigger the process of DNA mismatch repair (13); then this repair process leads to a repetitive cycle of futile mismatch repair where thymine is repetitively mispaired with O⁶MG and subsequently leads to growth arrest and apoptosis (14, 15).

A series of laboratory studies has shown that at least two mechanisms of resistance seem to be operational in mediating resistance to temozolomide. The first of these mechanisms involves removal of the methyl adduct on the O⁶-position of O⁶MG by AGT, which has been shown in both cell culture and xenograft studies to produce resistance to temozolomide (16–20). The second mechanism of resistance is related to a deficiency in DNA mismatch repair. This mechanism has been shown to confer resistance to temozolomide *in vitro* (21) and *in vivo* (22). The futile cycle created by the inability of the DNA mismatch repair proteins to correctly fix the methyl adducts is needed for methylating agents to mediate their cytotoxic effect. The deficiency of this DNA mismatch repair process results in tolerance of O⁶MG residues as well as other methyl adducts in DNA and, eventually, cell survival in the presence of persistent DNA damage.

Additional mechanisms of resistance to temozolomide may be operational with recent work suggesting a role for enhanced DNA base excision repair (23–25) and alterations in cell signaling involving the apoptotic pathway (26, 27).

The presence of chemotherapy resistance pathways is associated with poor tumor responses and patient survival in a variety of tumors. In melanoma cells, increased but variable AGT activity is found (28–31). There is higher AGT activity found in tumor cells than in normal skin cells and higher activity in metastatic tumors than in primary lesions. In addition, expression of AGT activity is higher in melanoma metastasis after chemotherapy with alkylating agents (28, 32).

Depletion of AGT, either with methylating agents that generate O⁶MG residues in DNA (33, 34) or with O⁶-alkylguanine (16, 35–41), renders cells more sensitive to methylator-induced cytotoxicity, presumably by way of increased formation of interstrand cross-links or initiation of a lethal cycle of mismatch repair. Dolan et al. (39, 40, 42) have reported that the substrate analogue O⁶-benzylguanine (O⁶BG) inhibits AGT activity and potentiates the cytotoxicity of both chloroethylating agents and methylating agents. They showed that O⁶BG binds AGT, transferring the benzyl moiety to the active-site cysteine (43). The reaction is very rapid and complete, making O⁶BG one of the strongest inhibitors of AGT. O⁶BG is not incorporated into DNA in living cells and reacts directly with both cytoplasmic and nuclear AGT. O⁶BG is now being used in clinical studies to assess the ability of AGT inhibition to overcome chemotherapy resistance in a variety of tumors (44–46).

When O⁶BG was given at concentrations of 10 to 30 mg/kg in mice, it has been reported that human tumor xenograft AGT is depleted within 30 minutes and depletion is maintained for 6 to 8 hours, after which endogenous regeneration of AGT occurs through synthesis of new protein (47, 48). In the present study, to determine an appropriate dose of O⁶BG to maximize AGT depletion with less toxicity in this model, we conducted O⁶BG dosing studies. The activity of AGT was markedly inhibited using a concentration of 3.5 mg/kg O⁶BG. Repeated dosing of O⁶BG has been shown to maintain depletion of AGT activity in tumors (49).

AGT depletion by O⁶BG has been shown to increase the cytotoxicity of temozolomide *in vitro* (50) and *in vivo* (6, 49, 51). Wedge et al. (49) have shown that the combination of the two agents given systemically can result in an increased therapeutic index for temozolomide in a human xenograft model. However, there is no significant difference between the groups with or without treatment of O⁶BG, even in the most pronounced effect in combination with 100 mg/kg systemic temozolomide. Whereas O⁶BG is known to inhibit AGT activity and, in several animal models, improves temozolomide efficacy *in vivo* against melanoma, the magnitude of the action of temozolomide is frequently limited by the synergistic toxicity that occurs when both agents are given systemically.

No previous studies have been done in the setting of regional temozolomide administration using systemic O^6 BG to inhibit AGT. Therefore, we then did a set of infusional treatments using two different temozolomide dosages and found marked prolongation of melanoma tumor quintupling time, increased tumor growth delay, and tumor regressions at both temozolomide dosages as compared with control treatments in animals not receiving O^6 BG, as well as in animals who received O^6 BG but had a sham (DMSO) infusion as shown in Table 1. Interestingly, there was no increase in limb toxicity seen in these animals.

In this report, we showed how the effect of regional temozolomide on an *in vivo* model having advanced extremity melanoma can be optimized using chemomodulation with O^6 BG. Modulation of chemoresistance pathways improves the therapeutic index of regional temozolomide-based therapy in our animal model of isolated limb infusion. All of these studies were done without the addition of tumor hyperthermia. These observations further support our earlier findings, using melphalan, that modulation of the tumor resistance pathways for chemotherapies used in regional infusional treatments is an effective novel strategy to improve the therapeutic index of this treatment approach (5). Our findings may offer a new approach to improve the efficacy of treatment for melanoma patients with regionally advanced disease and pave the way for a series of temozolomide-based regional therapy clinical trials.

Acknowledgments

We thank Gerald Olson, D.V.M, M.S., and Rick Leary.

References

- Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. *Surg Gynecol Obstet* 1989;169:1–6.
- Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. *Am J Surg* 2004;188:532–7.
- Grubbs EG, Abdel-Wahab O, Cheng TY, et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. *J Am Coll Surg* 2004;199:419–27.
- Grubbs EG, Ueno T, Abdel-Wahab O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. *Surgery* 2004;136:210–8.
- Abdel-Wahab OI, Grubbs E, Viglianti BL, et al. The role of hyperthermia in regional alkylating agent chemotherapy. *Clin Cancer Res* 2004;10:5919–29.
- Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. *Cancer Res* 1995;55:2853–7.
- Domoradzki J, Pegg AE, Dolan ME, Maher VM, McCormick JJ. Correlation between O^6 -methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of *N*-methyl-*N*'-nitro-*N*'-nitrosoguanidine. *Carcinogenesis* 1984;5:1641–7.
- Friedman HS, Keir S, Pegg AE, et al. O^6 -Benzylguanine-mediated enhancement of chemotherapy. *Mol Cancer Ther* 2002;1:943–8.
- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000;18:158–66.
- Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. *J Clin Oncol* 2004;22:2101–7.
- Pauly GT, Hughes SH, Moschel RC. Response of repair-competent and repair-deficient *Escherichia coli* to three O^6 -substituted guanines and involvement of methyl-directed mismatch repair in the processing of O^6 -methylguanine residues. *Biochemistry* 1994;33:9169–77.
- Armstrong MJ, Galloway SM. Mismatch repair provokes chromosome aberrations in hamster cells treated with methylating agents or 6-thioguanine, but not with ethylating agents. *Mutat Res* 1997;373:167–78.
- Aquilina G, Hess P, Branch P, et al. A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. *Proc Natl Acad Sci U S A* 1994;91:8905–9.
- D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. *Mol Pharmacol* 1998;54:334–41.
- Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. *Proc Natl Acad Sci U S A* 1999;96:10764–9.
- Yarosh DB, Hurst-Calderone S, Babich MA, Day RS III. Inactivation of O^6 -methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O^6 -methylguanine as a free base. *Cancer Res* 1986;46:1663–8.
- Pegg AE. Mammalian O^6 -alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. *Cancer Res* 1990;50:6119–29.
- Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. *Mutat Res* 1990;233:117–26.
- Pegg AE, Byers TL. Repair of DNA containing O^6 -alkylguanine. *FASEB J* 1992;6:2302–10.
- Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O^6 -alkylguanine-DNA alkyltransferase. *Prog Nucleic Acid Res Mol Biol* 1995;51:167–223.
- Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. *Cancer Res* 1996;56:5375–9.
- Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. *Cancer Res* 1997;57:2933–6.
- Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. *Clin Cancer Res* 1999;5:2908–17.
- Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. *Blood* 2002;99:2241–4.
- Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. *Glia* 2002;40:44–54.
- Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. *Clin Cancer Res* 2002;8:2725–34.
- Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. *Biochem Pharmacol* 2002;63:1219–28.
- Moriwaki S, Nishigori C, Takebe H, Imamura S. O^6 -Alkylguanine-DNA alkyltransferase activity in human malignant melanoma. *J Dermatol Sci* 1992;4:6–10.
- Lee SM, Rafferty JA, Elder RH, et al. Immunohistological examination of the inter- and intracellular distribution of O^6 -alkylguanine DNA-alkyltransferase in human liver and melanoma. *Br J Cancer* 1992;66:355–60.
- Middleton MR, Lunn JM, Morris C, et al. O^6 -Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. *Br J Cancer* 1998;78:1199–202.
- Ma S, Eghazi S, Martenhed G, Ringborg U, Hansson J. Analysis of O^6 -methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. *Melanoma Res* 2002;12:335–42.

32. Spiro T, Liu L, Gerson S. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. *Forum (Genova)* 2000;10:274–85.
33. Zlotogorski C, Erickson LC. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. *Carcinogenesis* 1984;5:83–7.
34. Aida T, Bodell WJ. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and *cis*-diamminedichloroplatinum(II) in human gliad-derived cell lines. *Cancer Res* 1987;47:1361–6.
35. Gerson SL, Trey JE, Miller K. Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of *O*⁶-alkylguanine-DNA alkyltransferase. *Cancer Res* 1988;48:1521–7.
36. Dolan ME, Corsico CD, Pegg AE. Exposure of HeLa cells to *O*(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. *Biochem Biophys Res Commun* 1985;132:178–85.
37. Dolan ME, Morimoto K, Pegg AE. Reduction of *O*⁶-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with *O*⁶-alkylguanines. *Cancer Res* 1985;45:6413–7.
38. Dolan ME, Young GS, Pegg AE. Effect of *O*⁶-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. *Cancer Res* 1986;46:4500–4.
39. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian *O*⁶-alkylguanine-DNA alkyltransferase activity by *O*⁶-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. *Proc Natl Acad Sci U S A* 1990;87:5368–72.
40. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of *O*⁶-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. *Cancer Res* 1991;51:3367–72.
41. Mitchell RB, Moschel RC, Dolan ME. Effect of *O*⁶-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. *Cancer Res* 1992;52:1171–5.
42. Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE. Modulation of mammalian *O*⁶-alkylguanine-DNA alkyltransferase *in vivo* by *O*⁶-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. *Cancer Commun* 1990;2:371–7.
43. Pegg AE, Boosalis M, Samson L, et al. Mechanism of inactivation of human *O*⁶-alkylguanine-DNA alkyltransferase by *O*⁶-benzylguanine. *Biochemistry* 1993;32:11998–2006.
44. Spiro TP, Gerson SL, Liu L, et al. *O*⁶-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. *Cancer Res* 1999;59:2402–10.
45. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical trial and pharmacological study of *O*⁶-benzylguanine followed by carmustine in patients with advanced cancer. *Clin Cancer Res* 2000;6:3025–31.
46. Friedman HS, Kokkinakis DM, Pluda J, et al. Phase I trial of *O*⁶-benzylguanine for patients undergoing surgery for malignant glioma. *J Clin Oncol* 1998;16:3570–5.
47. Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of *O*⁶-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. *Biochem Pharmacol* 1993;45:483–91.
48. Kreklau EL, Kurpad C, Williams DA, Erickson LC. Prolonged inhibition of *O*(6)-methylguanine DNA methyltransferase in human tumor cells by *O*(6)-benzylguanine *in vitro* and *in vivo*. *J Pharmacol Exp Ther* 1999;291:1269–75.
49. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an *O*⁶-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. *Cancer Chemother Pharmacol* 1997;40:266–72.
50. Wedge SR, Porteous JK, May BL, Newlands ES. Potentiation of temozolomide and BCNU cytotoxicity by *O*(6)-benzylguanine: a comparative study *in vitro*. *Br J Cancer* 1996;73:482–90.
51. Wedge SR, Newlands ES. *O*⁶-Benzylguanine enhances the sensitivity of a glioma xenograft with low *O*⁶-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. *Br J Cancer* 1996;73:1049–52.

Molecular Cancer Therapeutics

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O⁶-benzylguanine

Tomio Ueno, Sae Hee Ko, Elizabeth Grubbs, et al.

Mol Cancer Ther 2006;5:732-738.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/5/3/732>

Cited articles This article cites 50 articles, 26 of which you can access for free at:
<http://mct.aacrjournals.org/content/5/3/732.full#ref-list-1>

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at:
<http://mct.aacrjournals.org/content/5/3/732.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/5/3/732>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.